神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100481709

このアイテムのアクセス数:484件（2026-05-15 23:39 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100481709 (fulltext) pdf 701 KB 196

メタデータ

ファイル出力

メタデータID
0100481709
アクセス権
open access
出版タイプ
Accepted Manuscript
タイトル
Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration
著者
Sotani, Rei ; Matsumiya, Wataru ; Kim, Kyung Woo ; Miki, Akiko ; Yasuda, Eriko ; Maeda, Yoshifumi ; Hara, Rumiko ; Kusuhara, Sentaro ; Nakamura, Makoto
著者名
Sotani, Rei
著者ID
A2179
研究者ID
1000030707120
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=b74cc616b1a3d918520e17560c007669
著者名
Matsumiya, Wataru
松宮, 亘
マツミヤ, ワタル
所属機関名
医学研究科
著者名
Kim, Kyung Woo
著者ID
A1504
研究者ID
1000010726988
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=704fe343d155a8da520e17560c007669
著者名
Miki, Akiko
三木, 明子
ミキ, アキコ
所属機関名
医学部附属病院
著者名
Yasuda, Eriko
著者名
Maeda, Yoshifumi
著者名
Hara, Rumiko
著者ID
A1380
研究者ID
1000040437463
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=32b946773fbb21da520e17560c007669
著者名
Kusuhara, Sentaro
楠原, 仙太郎
クスハラ, センタロウ
所属機関名
医学研究科
著者ID
A0882
研究者ID
1000080273788
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=82142348522a81ad520e17560c007669
著者名
Nakamura, Makoto
中村, 誠
ナカムラ, マコト
所属機関名
医学研究科
言語
English (英語)
収録物名
Graefe's Archive for Clinical and Experimental Ophthalmology
巻(号)
261(8)
ページ
2359-2366
出版者
Springer Nature
刊行日
2023-08
公開日
2024-04-01
抄録
Purpose: The aim of this study is to explore the clinical features and associated factors of intraocular inflammation (IOI) following intravitreal brolucizumab (IVBr) administration for neovascular age-related macular degeneration (nAMD). Methods: This retrospective study included 87 eyes from 87 Japanese patients with nAMD who were followed up for 5 months after the initial administration of IVBr as switching therapy. Clinical pictures of IOI post-IVBr and changes in best corrected visual acuity (BCVA) at 5 months were evaluated between eyes with and without IOI (non-IOI). The association between IOI and baseline factors (age, sex, BCVA, hypertension, and/or arteriosclerotic changes in the fundus, subretinal hyperreflective material [SHRM], and macular atrophy) was evaluated. Results: Of the 87 eyes, 18 (20.6%) developed IOI and 2 (2.3%) developed retinal artery occlusion. There were 9 (50%) cases of posterior or pan-uveitis among eyes with IOI. The mean interval from initial IVBr administration to IOI was 2 months. The mean changes in logMAR BCVA at 5 months were significantly worse in IOI eyes than in non-IOI eyes (0.09 ± 0.22 vs. − 0.01 ± 0.15, P = 0.03). There were 8 (44.4%) and 7 (10.1%) cases of macular atrophy and 11 (61.1%) and 13 (18.8%) cases of SHRM in the IOI and non-IOI groups, respectively. SHRM and macular atrophy were significantly associated with IOI (P = 0.0008 and P = 0.002, respectively). Conclusion: In IVBr therapy for nAMD, eyes with SHRM and/or macular atrophy should be observed more meticulously, given the increased risk of developing IOI, which is associated with insufficient BCVA gain.
キーワード
Brolucizumab
Intraocular inflammation
Uveitis
Factor
Age-related macular degeneration
Retinal artery occlusion
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00417-023-06036-x
関連情報
DOI
https://doi.org/10.1007/s00417-023-06036-x